Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ

Research site

(Unclaimed)

Location

4550 East Bell Road Suite 170, Phoenix, Arizona, United States of America

Site insights

Top conditions

Top treatments

Baricitinib

Methotrexate

Ixekizumab

Vedolizumab

Upadacitinib

Mirikizumab

Adalimumab

Iloprost

RO7123520

Secukinumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 28 total trials

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Enrolling

Crohn's Disease

Drug: Mirikizumab

A Study of Baricitinib in Participants With Rheumatoid Arthritis (RA-BRANCH)

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...

Enrolling

Rheumatoid Arthritis

Drug: Baricitinib

Drug: TNF Inhibitor

A Study of CDPATH™ to Help Manage and Treat Crohn's Disease (COMPASS-CD)

CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. Th...

Active, not recruiting

Crohn's Disease

Other: Blood Draw

Other: CDPATH™

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (RESOLUTION-1)

The main purpose of this study is to assess the safety and efficacy of peresolimab in adult participants with moderately-to-severely active rheumatoi...

Active, not recruiting

Joint Diseases

Arthritis

Drug: Peresolimab

Drug: Placebo

A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

The primary objectives of the study are to evaluate the efficacy of BIIB059 (litifilimab) compared with placebo in reducing skin disease activity mea...

Enrolling

Subacute Cutaneous Lupus Erythematosus

Chronic Cutaneous Lupus Erythematosus

Drug: BIIB059 (litifilimab)

Drug: Placebo

COVID-19 VaccinE Response in Rheumatology Patients (COVER)

The COVID-19 VaccinE Response in Rheumatology patients (COVER) study is a multicenter randomized controlled trial designed to evaluate the efficacy a...

Enrolling

Psoriatic Arthritis

Spondylarthritis

Drug: Abatacept

Drug: Baricitinib

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how s...

Enrolling

Systemic Lupus Erythematosus

Drug: Upadacitinib

Drug: Placebo